MAPT and Alzheimer disease: Interestingly, IGF2 levels are increased in the cerebrospinal fluid (CSF) of AD patients, and this increase is correlated with the levels of the AD-associated CSF biomarkers phosphorylated tau and Aβ42 (Åberg et al., 2015; Heywood et al., 2015).